Candidly, this is actually quite a bit better news than I had expected. Merck will keep some R&D jobs open in Oss, per Reuters reporting this morning:
. . . .Organon said on Thursday that Merck has now agreed to keep 486 of the 1000 research and development jobs in the Netherlands, and to set up a new Dutch research centre focused on supporting all of Merck’s therapeutic areas as well as emerging economies. . . .
Separately, FDA denied Merck’s application to expand the label for Gardasil, to older women in the US.